RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting clinical trials that explore combination therapies involving novel antibody-drug conjugates (ADCs), specifically, RC88 and RC108, and the PD-1 inhibitor sintilimab injection, TYVYT. As per the agreement, Innovent Biologics will supply […]
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China suffering from difficult-to-treat cancers. The two parties plan to expedite the development and commercialization of a couple of important clinical stage oncology assets of Sanofi, which are SAR408701 (tusamitamab ravtansine; […]
Innovent Biologics and Shenzhen Chipscreen Biosciences have entered into a major collaboration to assess the potential of a combination therapy for advanced colorectal cancer. The combination will include Innovent’s Tyvyt (sintilimab injection), a PD-1 monoclonal antibody, alongside IBI305, a proposed biosimilar to Roche’s bevacizumab. These two drugs will be evaluated alongside Chidamide, an epigenetic modulator […]
